by Bill Sardi and Timothy Hubbell
May 22, 2008

from LewRockwell Website

It works 100% of the time to eradicate cancer completely, and cancer does not recur even years later. That is how researchers describe the most convincing cancer cure ever announced.

The weekly injection of just 100 billionths of a gram of a harmless glyco-protein (a naturally-produced molecule with a sugar component and a protein component) activates the human immune system and cures cancer for good, according to human studies among breast cancer and colon cancer patients, producing complete remissions lasting 4 and 7 years respectively.

This glyco-protein cure is totally without side effect but currently goes unused by cancer doctors.

Normal Gc protein (also called Vitamin-D binding protein), an abundant glyco-protein found in human blood serum, becomes the molecular switch to activate macrophages when it is converted to its active form, called Gc macrophage activating factor (Gc-MAF). Gc protein is normally activated by conversion to Gc-MAF with the help of the B and T cells (bone marrow-made and thymus gland-made white blood cells).

But, as researchers explain it themselves, cancer cells secrete an enzyme known as alpha-N-acetylgalactosaminidase (also called Nagalase) that completely blocks conversion of Gc protein to Gc-MAF, preventing tumor-cell killing by the macrophages. This is the way cancer cells escape detection and destruction, by disengaging the human immune system. This also leaves cancer patients prone to infections and many then succumb to pneumonia or other infections.

The once-weekly injection of minute amounts of Gc-MAF, just 100 nanograms (billionths of a gram), activates macrophages and allows the immune system to pursue cancer cells with vigor, sufficient to produce total long-term cures in humans.

Nobuto Yamamoto, director of the Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania, says this is,

“probably the most potent macrophage activating factor ever discovered.”

A MACROPHAGE OVERCOMES AND EATS A CANCER CELL
FROM THE UPJOHN COMPANY, THE IMMUNE SYSTEM

 

A MACROPHAGE OVERCOMES AND EATS A CANCER CELL
FROM THE UPJOHN COMPANY, THE IMMUNE SYSTEM

Once a sufficient number of activated macrophages are produced, another Gc-MAF injection is not needed for a week because macrophages have a half-life of about six days.

After 16-22 weekly doses of Gc-MAF the amount of Nagalase enzyme fell to levels found in healthy people, which serves as evidence tumors have been completely eliminated. The treatment was fool-proof - it worked in 100% of 16 breast cancer patients and there were no recurrent tumors over a period of 4 years, says a report in the January 15 issue of the International Journal of Cancer. [International Journal Cancer.2008 January15; 122(2):461-7]

In another startling follow-up report by Dr. Yamamoto and colleagues, published in the upcoming July issue of Cancer Immunology Immunotherapy, Gc-MAF therapy totally abolished tumors in 8 colon cancer patients who had already undergone surgery but still exhibited circulating cancer cells (metastases).

After 32-50 weekly injections,

”all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells,” said researchers, an effect that lasted 7 years with no indication of cancer recurrence either by enzyme activity or CT scans, said researchers.

[Cancer Immunology, Immunotherapy Volume 57, Number 7 / July 2008]

Published in an early online edition of this journal, this confirming report has received no attention by the new media so far, despite its striking importance.

Gc-MAF treatment for cancer has been agonizingly slow to develop. Dr. Yamamoto first described this immuno-therapy in 1993. [The Journal of Immunology, 1993 151 (5); 2794-2802]

Untreated mice ○ Mice given macrophage activating factor

In a similar animal experiment published in 2003, researchers in Germany, Japan and the United States collaborated to successfully demonstrate that after they had injected macrophage activating factor (Gc-MAF) into tumor-bearing mice, it totally eradicated tumors. [Neoplasia 2003 January; 5(1): 32–40]

In 1997 Dr. Yamamoto injected GcMAF protein into tumor-bearing mice, with the same startling results. A single enzyme injection doubled the survival of these mice and just four enzyme injections increased survival by 6-fold. [Cancer Research 1997 Jun 1; 57(11):2187-92]

In 1996 Dr. Yamamoto reported that all 52 cancer patients he had studied carried elevated blood plasma levels of the immune inactivating alpha-N-acetylgalactosaminidase enzyme (Nagalase), whereas healthy humans had very low levels of this enzyme. [Cancer Research 1996 Jun 15; 56(12):2827-31]

In the early 1990s, Dr. Yamamoto first described how the human immune system is disengaged by enzymes secreted from cancer cells, even filing a patent on the proposed therapy. [US Patent 5326749, July 1994; Cancer Research 1996 June 15; 56: 2827-31]

Activated Gc protein has been used in humans at much higher doses without side effect. This Gc macrophage activating factor (Gc-MAF) has been shown to be effective against a variety of cancers including breast, prostate, stomach, liver, lung, uterus, ovary, brain, skin, head/neck cancer, and leukemia.

Although GcMAF is also called Vitamin-D binding protein, the activation of macrophages does not require Vitamin D.

It cannot be said the Gc-MAF cancer cure has gone unheralded. Reuters News covered this developing story in January. But the news story still did not receive top billing nor did it fully elucidate the importance of the discovery, actually made years ago, that the human body is capable of abolishing cancer once its immune system is properly activated.

Gc-MAF is a naturally made molecule and is not patentable, though its manufacturing process is patent protected.

There is no evidence of any current effort to commercialize this therapy or put it into practice. Should such an effective treatment for cancer come into common practice, the income stream from health-insurance plans for every oncology office and cancer center in the world, would likely be reduced to the point of financial insolvency and hundreds of thousands of jobs would be eliminated.

The National Cancer Institute estimates cancer care in the U.S. costs ~$72 billion annually (2004). Furthermore, about $55 billion of cancer drugs are used annually, none which have not significantly improved survival rates throughout the history of their use.

If a typical cancer patient had to undergo 30 GcMAF injections at a cost of $150 per injection, that would cost ~$4500, not counting doctor’s office visits and follow-up testing. For comparison, gene-targeted cancer drugs range from $13,000 to $100,000 in cost per year and produce only marginal improvements in survival (weeks to months). [Targeted Oncology 2007 April, 2 (2); 113-19]

Up to this point, the National Cancer Institute is totally silent on this discovery and there is no evidence the cancer care industry plans to quickly mobilize to use this otherwise harmless treatment.
 

Addendum

Sadly, the treatment you have just read about is not available anywhere. Its inventor is attempting to patent a version of it to profiteer off of it even though there is no need to improve upon the GcMAF molecule - it worked without failure to completely cure four different types of cancer with no long-term remissions and without side effect.

 

While GcMAF is produced by every healthy adult, there are no centers available to extract it from blood samples and inject it into patients with malignancies. Hopefully, someday, doctors will write protocols to do this and submit them to institutional review boards so GcMAF treatment can be performed on an experimental basis.

 

GcMAF is a naturally-made molecule that cannot be patented.

 

This article was written to reveal that there are proven cancer cures that go unused. Of interest, not one oncologist has requested information about GcMAF since this article was written, while I have been barraged with inquires from cancer patients, their families and some interested physicians who are not cancer doctors.

-Bill Sardi
 

Help NHF get the word out about GcMAF and other proven cures for cancer that are being ignored. Learn how NHF is the leading health freedom organization, for example, battling for your right to maintain access to dietary supplements without restrictions imposed by quasi-governing bodies like CODEX and our other missions.

Search the NHF website for more helpful information and become a member by clicking here.

Macrophage Activation May Suppress Breast Cancer Metastasis
by David Douglas
NEW YORK

February 20, 2008

Reuters Health

 

Vitamin D-binding protein-derived macrophage activating factor (Gc-MAF) appears to be an effective immunotherapeutic agent in patients with metastatic breast cancer, according to US and Japanese researchers.

"Serum vitamin D-binding protein – known as Gc protein – is the precursor of the principal macrophage activating factor," lead investigator Dr. Nobuto Yamamoto told Reuters Health.

"Treatment of purified Gc protein with beta-galactosidase and sialidase generates Gc-MAF," he added, "the most potent macrophage activating factor ever discovered, which produces no side effect in humans."

Dr. Yamamoto of the Socrates Institute for Therapeutic Immunology, Philadelphia and colleagues note that in vitro studies show that macrophages treated with Gc-MAF have a highly tumoricidal effect in mammary adenocarcinomas.

To investigate whether the approach can be effective in humans, the researchers studied 16 non-anemic breast cancer patients who were given,

"a minute amount – 100 nanograms per week – of Gc-MAF," Dr. Yamamoto said.

The researchers found that after 16 to 22 Gc-MAF doses, initially elevated nagalase levels, which reflect the tumor burden, fell to those found in healthy controls. Follow-up over 4 years showed that the level remained low and that there was no tumor recurrence, they report in the January 15th issue of The International Journal of Cancer.

The findings, the team concludes, clearly demonstrate

"the importance of focusing cancer immunotherapy on macrophage activation."

 

International Journal Cancer

2008 Jan 15; 122(2):461-7

Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (Gc-MAF).
Yamamoto N,

Suyama H,

Yamamoto N,

Ushijima N.
Division of Cancer Immunology and Molecular Biology

Socrates Institute for Therapeutic Immunology

Philadelphia, PA 19126-3305, USA.

nobutoyama@verizon.net

 

Serum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is proportional to tumor burden.

 

The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized beta-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed Gc-MAF) ever discovered, which produces no adverse effect in humans.

 

Macrophages treated in vitro with Gc-MAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of Gc-MAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of Gc-MAF (100 ng). As Gc-MAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase.

 

Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of Gc-MAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of Gc-MAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors.

 

This therapeutic procedure resulted in no recurrence for more than 4 years.

Cancer Immunology, Immunotherapy

2008 July 57 (7): online

Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, Gc-MAF
Nobuto Yamamoto

Hirofumi Suyama

Hiroaki Nakazato

Nobuyuki Yamamoto

Yoshihiko Koga
 

Abstract

Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein of colorectal cancer patients was lost or reduced because Gc protein is deglycosylated by serum α-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells.

 

Deglycosylated Gc protein cannot be converted to MAF, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized β-galactosidase and sialidase generated the most potent macrophage-activating factor (Gc-MAF) ever discovered, but it produces no side effect in humans. Macrophages treated with Gc-MAF (100 pg/ml) develop an enormous variation of receptors and are highly tumoricidal to a variety of cancers indiscriminately.

 

Administration of 100 nanogram (ng)/human maximally activates systemic macrophages that can kill cancerous cells. Since the half-life of the activated macrophages is approximately 6 days, 100 ng Gc-MAF was administered weekly to eight nonanemic colorectal cancer patients who had previously received tumor-resection but still carried significant amounts of metastatic tumor cells.

 

As Gc-MAF therapy progressed, the MAF precursor activities of all patients increased and conversely their serum Nagalase activities decreased. Since serum Nagalase is proportional to tumor burden, serum Nagalase activity was used as a prognostic index for time course analysis of Gc-MAF therapy.

 

After 32–50 weekly administrations of 100 ng Gc-MAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells.

 

During 7 years after the completion of Gc-MAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients.